Alpha Score of 57 reflects moderate overall profile with moderate momentum, strong value, weak quality, moderate sentiment.
Pfizer Inc. (PFE) remains positioned within the healthcare sector with a neutral Alpha Score of 50. This aggregate score reflects a balanced distribution across momentum, value, quality, and sentiment sub-scores, which currently show no significant deviation from baseline expectations. The stock is trading in a range that suggests market participants are awaiting clearer catalysts to shift the current neutral sentiment. While recent discussions highlight Pfizer as a potential component for income-focused portfolios, the technical data indicates that the stock is not currently exhibiting strong directional momentum. Investors are monitoring how the company manages its post-pandemic product pipeline and capital allocation strategies, which are critical for long-term valuation shifts. With the P/E ratio and growth rates remaining stable, the stock continues to trade well within its 52-week range without testing extreme highs or lows. The lack of volatility in the current sub-scores suggests that the market is in a period of consolidation, waiting for updated financial guidance to dictate the next phase of price action. Watch for upcoming quarterly earnings reports to see if fundamental growth metrics provide the necessary data to improve the current neutral Alpha Score.
Pfizer Inc. (PFE) closed the session with little directional conviction, reflecting a broader trend of consolidation within the healthcare sector. The stock currently maintains an Alpha Score of 50, indicating a balanced but directionless profile across all core analytical pillars. Specifically, the momentum, value, quality, and sentiment sub-scores remain neutral, suggesting that market participants are currently lacking a clear catalyst to drive significant price action in either direction. With the stock trading well within its 52-week range, there is no immediate evidence of a breakout or a sustained decline. Current valuation metrics reflect a P/E ratio consistent with historical averages for the pharmaceutical industry, while recent growth rates remain steady but unremarkable. The lack of divergence in the underlying sub-scores reinforces a period of technical equilibrium for the equity. Investors appear to be waiting for more definitive fundamental signals or sector-wide developments before adjusting positions. Moving forward, market participants should monitor upcoming quarterly earnings reports and potential pipeline updates for any shifts in sentiment or quality indicators that could disrupt this current neutral stance.
Pfizer Inc. filed its 2025 10-K, detailing a year of significant portfolio adjustments and cost-management programs. The company continues to navigate the integration of major acquisitions, including Seagen, while executing multiple restructuring plans aimed at optimizing its manufacturing footprint and overall cost base. Financial operations in 2025 were marked by ongoing investments in research and development, particularly in the biopharma segment, and the management of various collaborative arrangements and licensing agreements. The company reported activity related to its equity method investments, including divestitures of its stake in Haleon. Pfizer also entered into new strategic agreements, such as the November 2025 arrangement with Metsera, involving payments linked to clinical trial milestones and regulatory approvals. The company maintains a focus on its core biopharma operations, with ongoing efforts to streamline research and development and manufacturing processes. Asset impairments and restructuring charges remain a component of the company's financial profile as it aligns its cost structure with current strategic priorities. The filing highlights the company's reliance on a concentrated portfolio of products, with the top eleven to twelve products representing a significant portion of its revenue base. Management continues to monitor the impact of these restructuring programs on its long-term financial health and operational efficiency.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 34.35M | $855.34M | NEW |
| Marshall Wace | 14.46M | $360.10M | NEW |
| D.E. Shaw David Shaw | 13.37M | $332.98M | NEW |
| Scion Asset Management Michael Burry | 6.00M | $152.88M | NEW |
| Point72 Steve Cohen | 5.64M | $140.32M | NEW |
| Hussman Investment Trust John Hussman | 42K | $1.05M | NEW |
| Appaloosa David Tepper | 2.41M | $77.9K | NEW |
Pfizer Inc. is a research-based global biopharmaceutical company founded in 1849 and headquartered in New York. It focuses on the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide, targeting developed and emerging markets to advance wellness, prevention, treatments, and cures for the most feared diseases. Operating in the health technology sector, specifically pharmaceuticals: major, Pfizer Inc. addresses critical areas such as oncology, rare diseases, internal medicine, inflammation and immunology, vaccines, anti-infectives, gene therapy, medicinal sciences, and precision medicine. Notable advancements include acquisitions like Global Blood Therapeutics in 2023 to bolster its biopharmaceutical portfolio, alongside recent clinical trial successes in prostate cancer, lung cancer, and bladder cancer therapies. With approximately 81,000 employees, Pfizer Inc. generates substantial revenue, reported at $63.63 billion for the fiscal year, and maintains a significant presence in the global market through innovative pipelines and partnerships.
Earnings calendar coming soon. Subscribe to get notified when PFE reports next.
Get earnings alerts →